Novaremed Secures Additional Financing and Strengthens Leadership
2.9.2019 12:38:00 EEST | Business Wire | Press release
Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, today announced that it has secured CHF2.6 million in additional financing from its existing shareholders and several new private investors. This brings the total financing raised by the company, since its inception, to CHF21 million. In addition, the company announced that Subhasis Roy, Novaremed’s COO since April 2018, will be stepping up and fulfilling the role of Interim CEO.
The recent funding and strengthened leadership team are both integral developments for Novaremed as the company accelerates its preparation towards initiating a Phase 2b study in Diabetic Neuropathic Pain (DNP). The company is pleased to have received positive feedback from the FDA from their recently conducted Pre-IND meeting, which sets the path forward for the IND opening of the Phase 2b study in DNP.
"This additional financing underscores the commitment of our shareholders and private investors, as well as their faith in Novaremed’s potential," said Harry Welten, Chairman of the Board of Novaremed. "Novaremed is well-positioned with a seasoned leadership team, led by Subhasis, to drive Novaremed’s clinical development and operations forward."
Notes to the Editor:
About Novaremed
Novaremed Ltd. was founded in 2008 in Israel and transferred its corporate headquarters to Novaremed AG, founded in November 2017 in Switzerland. Novaremed is developing NRD.E1, an orally active non-opioid small molecule with a new mechanism of action for the treatment of DNP. In a Phase 2a Proof of Concept study, NRD.E1 showed clinically relevant reduction in patient reported pain. Novaremed is currently preparing for a global Phase 2b study in DNP, expected to start in Q2/3 2020. For more information, visit www.novaremed.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190902005074/en/
Contact information
Subhasis Roy, Interim CEO/COO
Tel: +41 79 2075715
Email:
subhasis.roy@novaremed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bracco Launches BubbleGen™ Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT5.5.2026 15:00:00 EEST | Press release
Bracco Imaging,a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, unveiled its Early Access Program today to enable cell therapy developers to evaluate the company’s new BubbleGen™ technology for cell therapy. Bracco’s team will be showcasing BubbleGen, which is designed to support a range of streamlined cell therapy manufacturing processes, at the International Society for Cell & Gene Therapy (ISCT) 2026 conference held this week in Dublin, Ireland. Through the BubbleGen evaluation kit, academic and industry researchers can explore a new approach to cell separation. The technology uses buoyant microbubbles to isolate specific cells, offering an alternative to traditional magnetic bead-based methods. The initial test case supports CD3+ T cell selection and activation in a format commonly used in commercial CAR T-cell therapies, and the platform is designed to extend beyond standard workflows. Researchers can adapt the system to iso
Fleet Launch Customer NetJets Takes Delivery of First Three Cessna Citation Ascend Midsize Business Jets5.5.2026 15:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, achieved a major milestone as the first three Cessna Citation Ascend business jets were delivered to fleet launch customer NetJets. NetJets, which operates the world's largest, most diverse private jet fleet, is the first private fleet operator to take delivery and begin operations with the Cessna Citation Ascend. Setting new standards in performance, comfort and operational efficiency for the midsize business jet market, the Citation Ascend builds on the longstanding relationship between Textron Aviation and NetJets by offering owners a seamless progression of advanced aircraft designed to deliver exceptional reliability, efficiency and luxury. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505495566/en/ Fleet launch customer NetJets takes delivery of first three Cessna Citation Ascend midsize business jets. (Photo Credit: Textron Aviation) “The Citation Ascend re
ATLAS Infrastructure Cornerstones United Utilities £800m Equity Placement5.5.2026 14:12:00 EEST | Press release
ATLAS Infrastructure (“ATLAS”) is a specialist Global Listed Infrastructure investor managing capital on behalf of its funds and long-term institutional clients. ATLAS has been an investor in UU since 2019 and, following the recent equity placement, ATLAS’s actively managed accounts hold a ~6.6% voting and economic interest in United Utilities plc (“UU”). ATLAS recognises the positive new direction established for the UK water sector and welcomes the opportunity to support UU management’s investment plan which will deliver the critical infrastructure required to support housing and industrial growth across North West England, as well as playing a crucial role in supporting nationally important initiatives related to AI data centres and sustainable energy. ATLAS strongly supports UU’s decision to raise new equity in order to accelerate its investment program through providing significant balance sheet capacity and financial flexibility through to the end of AMP8 in 2030. ATLAS values th
Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent5.5.2026 13:37:00 EEST | Press release
Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to Biopharma, today announces the appointments of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent. With extensive senior leadership experience across top-tier life-sciences investment funds, pharma and Biopharma companies, Elaine Caughey and Sarah Shackelton bring deep expertise in life sciences operations, investment, recruitment, and team building. Their appointments are synergistic and aligned with Jeito’s strategy, combining complementary skills across the full drug value chain to support portfolio company development and advance breakthrough therapies for patients. Building on a series of recent high-profile hires — including Samit Hirawat, M.D. as Strategic Medical Advisor, bringing senior leadership and clinical development experience at Novartis and Bristol Myers Squibb; Karin Van Baelen as Chief Regulatory Advisor, with
Datang Mobile, KPN, NEC and Wilus are Latest Licensors to Join Sisvel POS Patent Pool as Incentive Deadline Nears5.5.2026 11:02:00 EEST | Press release
Datang Mobile, KPN, NEC and Wilus have become the latest licensors in the Sisvel point of sale (POS) patent pool. They join seven other patent owners in making their 2G-5G cellular portfolios available through the programme: BlackBerry, Huawei, JVCKENWOOD, LG Electronics, Nokia, Sisvel and SK Telecom. The period for Sisvel POS licensors to benefit from early participation incentives is set to close on 15 May. Cellular patent owners interested in becoming involved should contact Sisvel as soon as possible. The pool, which is the first in the market to address the POS vertical, was announced at the beginning of April, with Huawei, LG Electronics and Nokia as founding licensors. “We have received a great response from the market so far, and I am pleased to welcome Datang, KPN, NEC and Wilus as the latest licensors,” says POS programme manager Sven Törringer. “We have put together a formidable group of cellular technology innovators, and there are many more companies in the pipeline. I am
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom